Patents Assigned to SERVICIO ANDALUZ DE SALUD
-
Publication number: 20170290774Abstract: The present invention relates to a composition comprising a neurokinin-1 receptor antagonist and at least one excipient selected from an oil, a fatty acid or a polyol, as well as to an administration form for administering a formulation, wherein said administration form is selected from: inhalant, nebulization, vapor, smoke or aerosol and comprises said composition. In addition, the invention relates to said composition for use as medicament, said administration form for use as medicament, preferably said composition for use as medicament in the treatment of at least one disease of the respiratory tract, or said administration form for use as medicament in the treatment of at least one disease of the respiratory tract. Moreover, the invention also provides methods for producing said composition and said administration form, as well as a kit of parts comprising said composition and an administration device.Type: ApplicationFiled: July 24, 2015Publication date: October 12, 2017Applicants: PLUS VITECH, S.L., SERVICIO ANDALUZ DE SALUDInventors: Antonio Lara Ruiz, Manuel Vicente Salinas Martín
-
Publication number: 20170226472Abstract: The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.Type: ApplicationFiled: August 4, 2015Publication date: August 10, 2017Applicants: Universidad de Granada, Universidad de Jaén, Servicio Andaluz de SaludInventors: Juan Antonio Marchal Corrales, Gema Jiménez González, Cynthia Morata Tarifa, María Ángel García Chaves, Macarena Perán Quesada
-
VACCINE AGAINST ACINETOBACTER BAUMANNII BASED ON CELLULAR COMPONENTS DEFICIENT IN LIPOPOLYSACCHARIDE
Publication number: 20170065700Abstract: The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.Type: ApplicationFiled: May 5, 2015Publication date: March 9, 2017Applicants: VAXDYN, S.L., FUNDACIÓN PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SALUD DE SEVILLA, SERVICIO ANDALUZ DE SALUDInventors: Michael James McConnell, Meritxell García Quintanilla, Marina Pulido Toledano, María Pilar Pérez Romero, Jerónimo Pachón Díaz, Juan José Infante Viñolo -
Publication number: 20170052189Abstract: Method of obtaining useful data for diagnosing the presence of cancer in an individual and to determine the stage or degree of progression of the cancer. Also to determine response to therapy and group subjects into responders and non-responders. Kit or device comprising the elements necessary to carry out this method and its uses.Type: ApplicationFiled: April 28, 2015Publication date: February 23, 2017Applicant: SERVICIO ANDALUZ DE SALUDInventor: Manuel Vicente Salinas Martin
-
Publication number: 20160152579Abstract: The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show affinity for the alpha and gamma subtypes of the peroxisome proliferator-activated receptors (PPAR) and which, therefore, modulate the actions regulated by said receptors, such as inducing satiety, controlling ingestion and modulating metabolic effects, and thus are useful for the administration thereof as a pharmacological tool and as drugs for the treatment and/or prevention of metabolic diseases and cardiovascular diseases.Type: ApplicationFiled: July 11, 2014Publication date: June 2, 2016Applicants: Servicio Andaluz de Salud, Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS), Consejo Superior de Investigaciones Científicas (CSIC)Inventors: Ruth Pérez Fernández, María Nieves Fresno López, José Elguero Bertolini, Pilar Goya Laza, Ana Belén Torres Zaguirre, Fernando Rodíguez De Fonseca, Francisco Javier Pavón Morón, Manuel Macías González, Miguel Romero Cuevas
-
Publication number: 20150297613Abstract: The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide NK1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor. The result of the alteration to the peritumoral environment is a reduction in the size of the tumor, the prevention of its development and, optionally, the induction of its disappearance. The invention also relates to pharmaceutical compositions containing said peritumoral-environment-altering agents, either alone or combined with at least one other active ingredient, for the treatment of cancer.Type: ApplicationFiled: December 13, 2012Publication date: October 22, 2015Applicant: SERVICIO ANDALUZ DE SALUDInventors: Manuel Vicente Salinas Martin, María Carmen Lara Ruiz
-
Patent number: 9119873Abstract: A composition based on a poly-organosiloxane which is suitable for its use as a bolus in radiotherapy treatments. Other possible uses of this composition are the production of an immobilizing mask for radio surgery or cranial stereotaxy treatments and the production of an intraoral depressor.Type: GrantFiled: October 11, 2012Date of Patent: September 1, 2015Assignee: SERVICIO ANDALUZ DE SALUDInventor: Santiago Velázquez Miranda
-
Publication number: 20150218635Abstract: A method for obtaining useful data for the determination of an individual's risk of suffering from severe sensorineural hearing loss, preferably in Ménière's disease, primers useful in the determination and kit comprising same.Type: ApplicationFiled: December 14, 2012Publication date: August 6, 2015Applicants: FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD, SERVICIO ANDALUZ DE SALUD, AGENCIA PÚBLICA EMPRESARIAL SANITARIA HOSPITAL DE PONIENTE, SERVICIO GALEGO SAÚDE, FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FEInventors: Jose Antonio López Escamez, Miguel Ángel López Nevot, Irene Gazquez Pérez, Antonia María Moreno Casares, Alicia López Nevot, María Teresa Requena Navarro, Ismael Aran González, Andrés Soto Varela, Sofia Santos Pérez, Herminio Pérez Garrigues
-
Publication number: 20150087880Abstract: A composition based on a poly-organosiloxane which is suitable for its use as a bolus in radiotherapy treatments. Other possible uses of this composition are the production of an immobilizing mask for radio surgery or cranial stereotaxy treatments and the production of an intraoral depressor.Type: ApplicationFiled: October 11, 2012Publication date: March 26, 2015Applicant: SERVICIO ANDALUZ DE SALUDInventor: Santiago Velázquez Miranda
-
Publication number: 20140148439Abstract: The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome.Type: ApplicationFiled: December 16, 2011Publication date: May 29, 2014Applicants: SERVICIO ANDALUZ DE SALUD, INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACIONInventors: María Yolanda De Diego Otero, Lucia María Pérez Costillas, Ignacio Del Arco Herrera
-
Publication number: 20140045205Abstract: The present invention relates to a method and a kit for the diagnosis and/or prognosis of kidney injury comprising analysing a sample obtained from a patient and determining the activity of at least one aminopeptidase selected from aspartyl aminopeptidase, glutamyl aminopeptidase, alanyl aminopeptidase and leucyl-cystinyl aminopeptidase.Type: ApplicationFiled: November 10, 2011Publication date: February 13, 2014Applicants: UNIVERSIDAD DE GRANADA, SERVICIO ANDALUZ DE SALUD, UNIVERSIDAD DE JAENInventors: Antonio Osuna Ortega, Rosmary Wangensteen Fuentes, José Félix Vargas Palomares, Manuel Ramirez Sanchez
-
Publication number: 20130280259Abstract: The object of this invention is the use of an antibody or a fragment thereof specific against NK1, NK2 and/or NK3 receptors of cells, for the manufacture of a medicament for the therapeutic management of human cancer, by direct administration to a mammal, including humans, by inducing cell death or apoptosis of tumour cells, modification of peritumoural microenvironment (consisting of stromal cells, stromal matrix, and intra and peritumoural vascularisation) and/or inflammatory and/or immune response around the tumour. In particular, in the case of melanoma, carcinoma (specially, breast carcinoma, lung, digestive system, prostate, cervix, endometrium, ovary and bladder), leukaemia, lymphomas, neoplasms, such as neuroblastoma and sarcoma, such as osteosarcoma.Type: ApplicationFiled: August 12, 2011Publication date: October 24, 2013Applicant: SERVICIO ANDALUZ DE SALUDInventor: Manuel Vicente Salinas Martín
-
Publication number: 20130022582Abstract: The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal.Type: ApplicationFiled: October 22, 2010Publication date: January 24, 2013Applicants: CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES, SERVICIO ANDALUZ DE SALUD, HOSPITAL CLINIC DE BARCELONAInventors: Simón Méndez Ferrer, Álvaro Urbano Ispizua
-
Publication number: 20120141435Abstract: The invention relates to the use of olive leaf extracts for producing a pharmaceutical composition capable of inducing angiogenesis and vascularization. In general, the composition can be used for therapeutic applications in order to promote the differentiation of stem cells into endothelial progenitor cells (EPCs) and/or mature endothelial cells, as well as to induce the vessel formation from said endothelial cells. The vascularization-inducing angiogenic composition of the invention is intended for, inter alia, cardiovascular disease, ischemic processes in general, ulcers, and wound healing in both human and veterinary medicine.Type: ApplicationFiled: May 14, 2010Publication date: June 7, 2012Applicants: SANIDAD Y RESIDENCIAS 21, S.A., QUESPER R&D, S.L., SERVICIO ANDALUZ DE SALUDInventors: Jose Manuel Quesada Gomez, Raquel Maria Santiago Mora, Antonio Casado Diaz, Maria Dolores Luque De Castro